Melanoma cells have the ability to change back into a more embryonic cell type which may be a reason why they are resistant to certain anti-cancer treatments, like radiotherapy. One way they may do this is by switching on a signalling pathway called ‘Notch’. There is a way to shut down this pathway, and we are looking to see whether doing that keeps melanoma cells in a state that makes them liable to anti-cancer treatments. In early work we have shown that inhibiting Notch signalling does indeed enhance the ability of radiotherapy to treat melanoma. We are exploring exactly how this occurs and how to optimise the combination for potential use in patients in a clinical trial.